BeOne Medicines AG

ONC

$362.68

+0.25%

N/A+$0.90

Healthcare

Biotechnology

NASDAQ

Active Trading

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, ...

Key Metrics of ONC

Snapshot

Latest / TTM · 6 periods

Market Cap

$42.16B

ROCE

13.1%

EV / EBITDA

34.74x

+6.1% YoY

FCF Yield

3.1%

+0.3% YoY

Cash Conversion Cycle

191.1d

Current Ratio

3.40

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$25.14B	$22.68B	$18.48B	$19.45B	$33.13B	$42.16B
Enterprise ValueCompany value including debt and cash adjustments.	$21.46B	$19.41B	$16.23B	$17.90B	$30.59B	$38.20B
EV / SalesHow many dollars investors pay per dollar of sales.	18.24x	13.71x	6.60x	4.70x	5.72x	6.20x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-15.41x	-10.24x	-21.99x	-49.55x	49.59x	34.74x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	2.64	1.73	3.04	4.28	-4.13	-3.60

Returns + ROCE gauge

ROCE latest

13.1%

Prev year 7.0%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-23.8%	-45.7%	-24.9%	-19.4%	6.6%	14.3%
ROAProfit generated from total assets.	-17.1%	-31.4%	-15.2%	-10.9%	3.5%	7.2%
ROICReturn generated on invested operating capital.	-21.5%	-42.1%	-22.8%	-18.1%	5.2%	10.9%
ROCEOperating return on long-term capital used.	-20.7%	-36.4%	-30.2%	-15.3%	7.0%	13.1%
Earnings YieldEarnings as a percentage of market value.	-5.8%	-8.8%	-4.8%	-3.3%	0.9%	1.1%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-1.61B	$-1.97B	$-1.72B	$-633.29M	$981.83M	$1.41B
FCFECash flow available to equity holders after debt flows.	$-1.51B	$-2.03B	$-1.36B	$-488.22M	$1.83B	$1.44B
FCF YieldFree cash flow divided by market capitalization.	-6.4%	-8.7%	-9.5%	-3.4%	2.8%	3.1%
Income QualityHow well accounting earnings are backed by cash flow.	0.92	0.75	1.31	0.22	3.93	2.27
Capex / OCFShare of operating cash flow spent on capital expenditures.	-24.2%	-31.3%	-51.5%	-376.3%	16.5%	11.7%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	155.2d	51.3d	58.8d	67.9d	60.6d	63.5d
DIOAverage days inventory stays before being sold.	537.0d	359.7d	399.8d	304.1d	332.1d	356.4d
DPOAverage days the company takes to pay suppliers.	580.8d	375.6d	302.7d	248.8d	261.5d	228.8d
Operating CycleTime from buying inventory to collecting receivables.	692.2d	411.0d	458.5d	372.0d	392.7d	419.9d
Cash Conversion CycleNet days cash is tied in operations.	111.4d	35.5d	155.8d	123.2d	131.1d	191.1d

Snapshot

Latest / TTM: —

Market Cap

$42.16B

ROE

14.3%

FCF Yield

3.1%

Current Ratio

3.40

Upstream

Catalent Pharma SolutionsDelisted (formerly NYSE:CTLT, acquired by Novo Holdings December 2024)Internal Manufacturing - Hopewell, NJInternal Manufacturing - Guangzhou, ChinaInternal Manufacturing - Suzhou, ChinaWuXi AppTec / Shanghai Syn-The-AllHKEx:2359Generic API ManufacturersExcipients and Raw Material SuppliersSingle-Use Bioprocessing Suppliers

Downstream

McKesson Specialty HealthNYSE:MCK Cardinal Health Specialty DistributionNYSE:CAH AmgenNASDAQ:AMGN NovartisNYSE:NVS ZymeworksNASDAQ:ZYME Jazz PharmaceuticalsNASDAQ:JAZZ Royalty PharmaNASDAQ:RPRX Bristol-Myers SquibbNYSE:BMY BiocytogenHKEx:02315Global Patient Access (The Max Foundation)

Proxies

Genentech/RocheNYSE:RHHBY Gilead SciencesNASDAQ:GILD IncyteNASDAQ:INCY Seagen (Pfizer)NYSE:PFE

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

BeOne Medicines AG

Key Metrics of ONC

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of ONC

Upstream

Downstream

Proxies

Key Metrics of ONC

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of ONC

Upstream

Downstream

Proxies